Dissection of prodromal Alzheimer's disease.

@article{Sheng2018DissectionOP,
  title={Dissection of prodromal Alzheimer's disease.},
  author={Can Sheng and Yue Huang and Ying Han},
  journal={Frontiers in bioscience},
  year={2018},
  volume={23},
  pages={
          1272-1291
        }
}
Pathophysiological changes of Alzheimer's Disease (AD) begin decades before clinical symptoms become apparent, providing an important window for early diagnosis and intervention. Prodromal stage of AD, a great opportunity for effective treatment and postponing the disease onset, has drawn extensive attention. The application of different biomarkers including neuroimaging, biochemical substances and genes makes AD-related pathology detectable in vivo and exploring novel biomarkers with… 
View on PubMed
bioscience.org
7 Citations
Background Citations
3

Figures and Tables from this paper

7 Citations

Citation Type

Citation Type

Neuroimaging Advances in Preclinical Alzheimers disease
TLDR
Ways to detect the evidence of AD pathology in the preclinical stage and further intervene the process of disease are reviewed.
Biomarkers of dementia: from bench to clinical side
TLDR
It would be useful to dose biomarkers in less invasive samples (such as blood or urine) as like as to use OMICs technologies, including proteomics and metabolomics, to find more predictive and diagnostic biomarkers for AD.
Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy
TLDR
It is suggested that lowering Aβ is an unproven strategy, and it may be time to refocus on other targets for the treatment of this disease including pathological forms of tau.
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
TLDR
Connectomic approaches reveal a number of hubs in the olfactory system that are key interconnectors with the main hubs of network dysfunction in Alzheimer's and Parkinson's diseases, and why some neuronal populations are vulnerable while others are resistant to pathology and to what extent glia prevent and/or facilitate proteinopathy spreading.
Up-regulated Pro-inflammatory MicroRNAs (miRNAs) in Alzheimer’s disease (AD) and Age-Related Macular Degeneration (AMD)
TLDR
It is indicated that these 7 up-regulated miRNAs have the potential to interact with and down-regulate ~ 9460 target messenger RNAs (mRNAs) involved in the synchronization of amyloid production and clearance, phagocytosis, innate-immune, pro-inflammatory, and neurotrophic signaling and/or synaptogenesis in diseased tissues.
Highly Expressed Amyloid Beta-42 Of Aqueous Humor In Patients With Neovascular Macular Degeneration
TLDR
In nAMD patients, aβ42 was highly expressed in the aqueous humor but was not correlated with cognitive function.
Combining Visual Rating Scales for Medial Temporal Lobe Atrophy and Posterior Atrophy to Identify Amnestic Mild Cognitive Impairment from Cognitively Normal Older Adults: Evidence Based on Two Cohorts.
TLDR
The combined MTA and PA rating scales demonstrated practical diagnostic value for distinguishing aMCI patients from controls, suggesting its potential to serve as a convenient and reproducible method to assess the degree of atrophy in clinical settings.

References

SHOWING 1-10 OF 122 REFERENCES
Diagnosis of Alzheimer’s Disease with [18F]PET in Mild and Asymptomatic Stages
  • A. Drzezga
  • Psychology, Biology
    Behavioural neurology
  • 2009
TLDR
The purpose of this article is to describe the typical findings of [18F]FDG PET in different stages of AD and to demonstrate its value for early and reliable diagnosis of Alzheimer's disease, particularly ahead of the stage of dementia of the Alzheimer’s type.
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
The critical need for defining preclinical biomarkers in Alzheimer's disease
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies
TLDR
An overview of FDG-PET results in individuals at risk for developing dementia, including presymptomatic individuals carrying mutations responsible for early-onset familial AD, and the potential to combine different PET tracers and CSF markers of pathology to improve the early detection of AD.
Etiology and Pathogenesis of Late-Onset Alzheimer’s Disease
TLDR
This review discusses the prevalent ideas that have governed this research for several years, and challenges them with alternative findings suggesting a multifactorial etiology of late-onset AD.
Genome research in pre-dementia stages of Alzheimer's disease
TLDR
This study reviewed the loci related to phenotypes of AD, MCI and SCD from literature and performed the first meta-analyses evaluating the role of apolipoprotein E (APOE) in the risk of conversion from a healthy status toMCI andSCD and revealed APOE as genetic risk factor to convert from ahealthy status to MCI.
Revising the definition of Alzheimer's disease: a new lexicon
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Imaging biomarkers in tauopathies.
Structural Neuroimaging in the Detection and Prognosis of Pre-Clinical and Early AD
TLDR
Findings suggest that measures of structural change in mesial and lateral temporal, cingulate, parietal and midfrontal areas may facilitate the assessment of a treatment's ability to halt the progressive structural loss that accompanies clinical decline in MCI.
...
...